|
CHM-018
NE-CHMIMO (CHM-018) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. NE-CHMIMO is the 1-cyclohexylmethyl (instead of 1-pentyl) analogue of the first-generation synthetic cannabinoid JWH-018. The corresponding cyclohexylmethyl derivative of JWH-081 had also been reported several months earlier. Legal status In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as NE-CHMIMO are Schedule I Controlled Substance The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United State ...s. NE-CHMIMO is a controlled substance in Japan as of November 2019. See also References Designer drugs Naphthoylindoles CB1 receptor agonists {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
CHM-081
CHM-081 (SGT-4) is a recreational designer drug which is classed as a synthetic cannabinoid. It is from the naphthoylindole family, being the 1-cyclohexylmethyl instead of 1-pentyl analogue of JWH-081, and produces cannabis-like effects. It has been identified as an ingredient in synthetic cannabis products in various countries including the USA and Australia. See also * AB-CHMINACA * CHM-018 * Org 28611 Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suit ... References Naphthoylindoles Designer drugs CB1 receptor agonists CB2 receptor agonists Cyclohexyl compounds Methoxy compounds {{Cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-018
FUB-JWH-018 (also known as FUB-018) is a naphthoylindole-based synthetic cannabinoid, representing a molecular hybrid of JWH-018 and AB-FUBICA or ADB-FUBICA. Legal status In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as FUB-JWH-018 are Schedule I Controlled Substances. As of October 2015 FUB-JWH-018 is a controlled substance in China. See also * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * CHM-018 * FUB-144 * FUB-APINACA * FDU-PB-22 * FUB-PB-22 * MDMB-FUBICA * MDMB-FUBINACA MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for cannabinoid receptors and that has been sold online as a designer drug. The structure of MDMB-FUBINACA contains the ... References Designer drugs Naphthoylindoles 4-Fluorophenyl compounds {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Indole
Indole is an organic compound with the formula . Indole is classified as an aromatic heterocycle. It has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered pyrrole ring. Indoles are derivatives of indole where one or more of the hydrogen atoms have been replaced by substituent groups. Indoles are widely distributed in nature, most notably as amino acid tryptophan and neurotransmitter serotonin. General properties and occurrence Indole is a solid at room temperature. It occurs naturally in human feces and has an intense fecal odor. At very low concentrations, however, it has a flowery smell, and is a constituent of many perfumes. It also occurs in coal tar. It has been identified in cannabis. It is the main volatile compound in stinky tofu. When indole is a substituent on a larger molecule, it is called an ''indolyl group'' by systematic nomenclature. Indole undergoes electrophilic substitution, mainly at position 3 (see diagram in ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-CHMINACA
ADB-CHMINACA (also known as ADMB-CHMINACA and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. Side effects There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. Legal status In the United States, ADB-CHMINACA is a Schedule I controlled substance. Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014. Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014. ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015. ADB-CHMINACA is illegal in Switzerland as o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these designer drugs were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human tr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-CHMINACA
MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor, and has been sold online as a designer drug. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB1, and an EC50 of 0.330 nM. It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication. Legal status MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015. MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015. Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019. See also * AB-CHMINACA * ADB-CHMINACA * ADB-FUBINACA ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-CHMICA
MDMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA. Chemistry Several commercial samples of MDMB-CHMICA were found to exclusively contain the (''S'')-enantiomer based on vibrational and electronic circular dichroism spectroscopy and X-ray crystallography. An (S)-configuration for the ''tert''-leucinate group is unsurprising since MDMB-CHMICA is likely synthesized from the abundant and inexpensive "L" form of the appropriate ''tert''-leucinate reactant. Pharmacology MDMB-CHMICA acts as a highly potent full agonist of the CB1 receptor with an efficacy of 94% and an EC50 value of 0.14 nM, which is approximately 8 times lower than the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PX-3
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication. The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014. Legality Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015. See also * 5F-AB-PINACA * 5F-ADB * 5F-AMB * 5F-APINACA * AB-FUBINACA * AB-CHFUPYCA * AB-CHMINACA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADBICA ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a componen ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-CHMINACA
AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor (''K''i = 0.78 nM) and CB2 receptor (''K''i = 0.45 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent. Continuing the trend seen in other cannabinoids of this generation, such as AB-FUBINACA and AB-PINACA, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue. Side effects There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid. Legal status In 2015, AB-CHMINACA became a Schedule I controlled substance in the United States. AB-CHMINACA is an Anlage II controlled substance in Germany as of May 2015. As of October 2015 AB-CHMINACA is a controlled substance in China. AB-CHMINACA is illegal in Switzerland as of December 2015. AB-CHMINACA is a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synthetic Cannabinoid
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. These novel Psychoactive drug, psychoactive substances should not be confused with synthetic phytocannabinoids (obtained by chemical synthesis) or synthetic Cannabinoid, endocannabinoids from which they are distinct in many aspects. Typically, synthetic cannabinoids are sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the United States and United Kingdom since 2016. They have been marketed as herbal incense, or "herbal smoking blends", and sold under common names such as K2, spice, and synthetic marijuana. They are often labeled "not for human consumption" for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid leg ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Schedule I Controlled Substance
The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs. The legislation created five schedules (classifications), with varying qualifications for a substance to be included in each. Two federal agencies, the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA), determine which substances are added to or removed from the various schedules, although the statute passed by Congress created the initial listing. Congress has sometimes scheduled other substances through legislation such as the Hillory J. Farias and Samantha Reid Da ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
JWH-081
JWH-081 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid Cannabinoids () are several structural classes of compounds found primarily in the ''Cannabis'' plant or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoact ... agonist at both the CB1 and CB2 receptors. With a Ki of 1.2nM it is fairly selective for the CB1 subtype, its affinity at this subtype is measured at approximately 10x the affinity at CB2(12.4nM). It was discovered by and named after John W. Huffman. JWH-081 may be neurotoxic to animals when administered in high doses. Legal status In the United States, JWH-081 is a Schedule I Controlled Substance. As of October 2015, JWH-081 is a controlled substance in China. See also * JWH-018 * JWH-098 * JWH-164 * JWH-198 * JWH-210 References Designer drugs JWH cannabinoids Naphthoylindoles Naphthol ethers CB1 receptor agonists [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
